Figure 3
Dose-dependent sensitivity data (log10 GR50) from four datasets (retrieved from the GR metrics calculator and browser web-based tool) for nonmalignant and cancer cell lines treated with 18/96 identified compounds. Bortezomib has been included as a reference.
